Search results

infliximab (Remsima)

Rheumatoid arthritis: in combination with methotrexate, for the reduction of signs and symptoms as well as improvement in physical function in: adult patients with active disease when the response to disease-modifying antirheumatic drugs (DMARDs), including methotrexate has been inadequate; adult patients with severe, active and progressive disease not previously treated with methotrexate or other DMARDs.

infliximab (Inflectra)

Rheumatoid arthritis: in combination with methotrexate, for the reduction of signs and symptoms as well as improvement in physical function in: adult patients with active disease when the response to disease-modifying antirheumatic drugs (DMARDs), including methotrexate has been inadequate; adult patients with severe, active and progressive disease not previously treated with methotrexate or other DMARDs.

infliximab (Remicade)

treatment of severely active ulcerative colitis in children and adolescents aged 6 to 17 years who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine or azathioprine, or who are intolerant to or have medical contraindications for such therapies.

infliximab (Remicade)

treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine or azathioprine, or who are intolerant to or have medical contraindications for such therapies.

infliximab (Remicade)

Treatment of severe, active Crohn' s disease in paediatric patients

infliximab (Remicade)

for the treatment of ankylosing spondylitis

infliximab (Remicade)

Ulcerative colitis

infliximab (Remicade)

treatment of moderately active Crohn' s disease.

infliximab (Remicade)

moderately to severely active ulcerative colitis.

infliximab 100mg powder for intravenous infusion (Remicade)

for the treatment of fistulising, active Crohn's disease.

infliximab 100mg powder for intravenous infusion (Remicade)

Severe, active Crohn's disease

infliximab 100mg powder for intravenous infusion (Remicade)

Severe plaque psoriasis

NICE Multiple Technology Appraisal (MTA)

Healthcare Improvement Scotland advises on adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed.

March 2015 decisions news release

The Scottish Medicines Consortium (SMC) has announced this month that seven new medicines have been accepted for use in NHSScotland.